Tumor necrosis factor-α (TNF-α)

tumor necrosis factor-α (Tnf-α) is a small pro-inflammatory cytokine protein, the founding member of the Tnf superfamily. It is synthesized as a type II transmembrane precursor that is cleaved by the metalloprotease TACE/ADAM17 to release a soluble form, which assembles into a homotrimer. Tnf-α is produced chiefly by activated macrophages, but also by T-lymphocytes, natural killer cells, mast cells, and many non-immune cell types. It signals through two receptors, TNFR1 and TNFR2: TNFR1 engagement drives NF-κB and MAPK activation and, under some conditions, caspase-dependent apoptosis, while TNFR2 signaling is more restricted to immune and endothelial populations. Induction of Tnf-α is a canonical downstream event of innate immune sensing — for example, lipopolysaccharide acting through toll-like receptor 4 (TLR4) and NF-κB — and Tnf-α in turn amplifies the same axis, coordinating expression of Interleukin-6 (IL-6), Interleukin-1β (IL-1β), C-X-C motif chemokine ligand 8 (CXCL8), C-C motif chemokine ligand 2, PTGS2/COX-2, and adhesion molecules that recruit leukocytes to inflamed tissue.

Because it sits at this hub, Tnf-α is one of the most widely used readouts of inflammatory burden and one of the most heavily targeted proteins in medicine. Circulating Tnf-α is measured alongside IL-6, interferon gamma (Ifng), and C-reactive protein (CRP) in immunoassays and newer multiplexed biosensing platforms, both in cytokine-storm states and in chronic conditions ranging from osteoarthritis and osteoporosis to polycystic ovary syndrome, metabolic and adipose tissue dysfunction, and intervertebral disc disease. Sustained Tnf-α signaling contributes to cartilage degradation, bone resorption, insulin resistance, endothelial activation, and — via microglial activation in the central nervous system — the neuroinflammation implicated in Alzheimer's disease, often in concert with oxidative stress and reactive oxygen species. Therapeutically, Tnf-α blockade with monoclonal antibodies and receptor-Fc fusion proteins is standard care in rheumatoid arthritis, inflammatory bowel disease, psoriasis, and ankylosing spondylitis, at the cost of increased susceptibility to infection, reflecting Tnf-α's normal role in host defense. It also recurs as a top-ranked hub target in network pharmacology analyses of anti-inflammatory natural products such as quercetin, luteolin, and baicalein, typically appearing with IL-6 and PTGS2 in predicted protein–protein interaction cores.